Mahler brings more than 20 years of leadership experience spanning cell therapy, biopharmaceutical development, manufacturing, and global business management
Since 2022, we have grown threefold and our growth story is built on scale, scientific innovation and deep customer partnerships
New facility will open by October 2026 and house 500 process development specialists
New Shoolagiri plant strengthens Maiva’s global CDMO capabilities with advanced isolator technology, flexible production lines, and expanded capacity for complex injectable therapies
The company gets access to Lonza’s clinically validated SYNtecan linker-payload platform as it prepares an IND filing for its acute myeloid leukemia therapy in 2027
Tomoyuki Hasegawa has been appointed CEO of FUJIFILM Biotechnologies California
Veteran pharma and biotech executive brings over 20 years of commercial leadership experience to support LMS's global CDMO and API growth strategy
The newly commissioned facility strengthens the ’company’s capabilities in the development and manufacturing of generic and complex sterile injectable products
The approval is expected to support the company’s presence in regulated international markets and further strengthen its position as a reliable pharma manufacturing partner
The newly licensed platform enables precise control over both the drug-to-antibody ratio and payload attachment sites in single- and dual-payload ADCs
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
